These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 17221247)

  • 1. [Does cigarette smoking influence the survival of patients with prostate cancer?].
    Jäger T; Eisenhardt A; Rübben H; Lümmen G
    Urologe A; 2007 Apr; 46(4):397-400. PubMed ID: 17221247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
    Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [What do prostate cancer patients know about smoking? : Results of a bicentric questionnaire study (KRAUT study)].
    May M; Gilfrich C; Spachmann P; Maurer O; Dombrowski MK; Fritsche HM; Wöhr M; Brookman-May S; Karl T; Schostak M; Burger M; Lebentrau S
    Urologe A; 2016 Aug; 55(8):1078-85. PubMed ID: 27364819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men.
    Gong Z; Agalliu I; Lin DW; Stanford JL; Kristal AR
    Cancer Causes Control; 2008 Feb; 19(1):25-31. PubMed ID: 17906959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smoking and risk of total and fatal prostate cancer in United States health professionals.
    Giovannucci E; Rimm EB; Ascherio A; Colditz GA; Spiegelman D; Stampfer MJ; Willett WC
    Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 1):277-82. PubMed ID: 10207628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smoking and risk of fatal prostate cancer in a prospective U.S. study.
    Rohrmann S; Genkinger JM; Burke A; Helzlsouer KJ; Comstock GW; Alberg AJ; Platz EA
    Urology; 2007 Apr; 69(4):721-5. PubMed ID: 17445658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Association of a positive family history with histopathology and clinical course in early-onset prostate cancer].
    Herkommer K; Paiss T; Merz M; Gschwend JE; Kron M
    Urologe A; 2006 Dec; 45(12):1532-9. PubMed ID: 17004091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.
    Valicenti RK; DeSilvio M; Hanks GE; Porter A; Brereton H; Rosenthal SA; Shipley WU; Sandler HM;
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1064-71. PubMed ID: 16979837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam.
    Bul M; van Leeuwen PJ; Zhu X; Schröder FH; Roobol MJ
    Eur Urol; 2011 Apr; 59(4):498-505. PubMed ID: 21334136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic importance of tobacco use in men receiving definitive prostate brachytherapy.
    Taira AV; Merrick GS; Galbreath RW; Butler WM; Bennett A; Adamovich E; Lief JH; Wallner KE
    Brachytherapy; 2012; 11(6):446-51. PubMed ID: 22405981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
    Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
    Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective study of smoking and risk of prostate cancer.
    Adami HO; Bergström R; Engholm G; Nyrén O; Wolk A; Ekbom A; Englund A; Baron J
    Int J Cancer; 1996 Sep; 67(6):764-8. PubMed ID: 8824546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL.
    Ang M; Rajcic B; Foreman D; Moretti K; O'Callaghan ME
    BJU Int; 2016 Apr; 117 Suppl 4():68-75. PubMed ID: 26890320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial.
    Wiegel T; Bartkowiak D; Bottke D; Thamm R; Hinke A; Stöckle M; Rübe C; Semjonow A; Wirth M; Störkel S; Golz R; Engenhart-Cabillic R; Hofmann R; Feldmann HJ; Kälble T; Siegmann A; Hinkelbein W; Steiner U; Miller K
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):288-94. PubMed ID: 25445556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical assessment of prebiopsy parameters for predicting prostate cancer metastasis and mortality.
    van Leeuwen PJ; van den Bergh RC; Wolters T; Zhu X; Bul M; Schröder FH; Bangma CH; Roobol MJ
    Can J Urol; 2011 Dec; 18(6):6018-24. PubMed ID: 22166329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of smoking on prostate cancer survival: a cohort analysis in Barcelona.
    Murta-Nascimento C; Romero AI; Sala M; Lorente JA; Bellmunt J; Rodero NJ; Lloreta J; Hospital À; Burón A; Castells X; Macià F
    Eur J Cancer Prev; 2015 Jul; 24(4):335-9. PubMed ID: 25075878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Epidemiology of lung cancer].
    Deppermann KM
    Internist (Berl); 2011 Feb; 52(2):125-9. PubMed ID: 21279317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smoking and aggressive prostate cancer: a review of the epidemiologic evidence.
    Zu K; Giovannucci E
    Cancer Causes Control; 2009 Dec; 20(10):1799-810. PubMed ID: 19562492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The parameter "relative survival": Analysis of regional cancer registry data for prostate cancer].
    Leuchter M; Kalata P; Hildebrandt G; Zettl H; Hakenberg OW
    Urologe A; 2016 Feb; 55(2):156-66. PubMed ID: 26358437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics.
    Abdollah F; Sun M; Schmitges J; Thuret R; Bianchi M; Shariat SF; Briganti A; Jeldres C; Perrotte P; Montorsi F; Karakiewicz PI
    J Urol; 2012 Jul; 188(1):73-83. PubMed ID: 22578732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.